A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 1/Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

Key facts

Study ID
NCT02574078
Run by
Bristol-Myers Squibb
People needed
341
Starts
2015-11-23
Expected to finish
2020-04-15
Last updated by the study team
2021-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.